Search Results for: 43

— Event to Highlight Company’s Two Phase 2 Clinical Programs: Treatment of Irritable Bowel Syndrome with Constipation and Prevention of C. difficile Infection — — Scheduled for Thursday, December 10, 2015 — ROCKVILLE, Md., Nov. 19, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the gut […]

— Initiated Phase 2b Proof-of-Concept Clinical Trial for the Prevention of C. difficile Infection and Antibiotic Associated Diarrhea — — Initiated Second Phase 2 Clinical Trial to Evaluate the Sustainability of Reduced Methane Production in Patients with Irritable Bowel Syndrome with Constipation — — Conference Call Today, November 5, 2015, at 4:30 p.m. EST —

— Conference Call Scheduled for Thursday, November 5, 2015 at 4:30 p.m. EST — ROCKVILLE, Md., Oct. 19, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, intends to release its financial results for the three and nine months ended September

— Trial to Evaluate the Ability of SYN-010 to Sustain the Reduction of Methane Production in the Gut for Patients who have Completed First Phase 2 Clinical Trial of SYN-010 — — Methane Production is Perceived as the Underlying Cause of Pain, Bloating and Constipation Associated with IBS-C — ROCKVILLE, Md., Oct. 8, 2015 /PRNewswire/

ROCKVILLE, Md., July 16, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, today announced that it has priced an underwritten public offering of 13.3 million shares of common stock at a price of $3.00 per share, for expected gross proceeds

ROCKVILLE, Md., March 2, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that preclinical results supporting the development of SYN-005 for the treatment of Pertussis will be highlighted at ECCMID 2015 (European Congress of Clinical Microbiology